JP2024505570A5 - - Google Patents
Info
- Publication number
- JP2024505570A5 JP2024505570A5 JP2023546482A JP2023546482A JP2024505570A5 JP 2024505570 A5 JP2024505570 A5 JP 2024505570A5 JP 2023546482 A JP2023546482 A JP 2023546482A JP 2023546482 A JP2023546482 A JP 2023546482A JP 2024505570 A5 JP2024505570 A5 JP 2024505570A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144408P | 2021-02-01 | 2021-02-01 | |
| US63/144,408 | 2021-02-01 | ||
| PCT/US2022/014601 WO2022165362A2 (en) | 2021-02-01 | 2022-01-31 | Epigenetic gene regulation to treat neurological diseases and pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024505570A JP2024505570A (ja) | 2024-02-06 |
| JP2024505570A5 true JP2024505570A5 (https=) | 2025-02-10 |
| JPWO2022165362A5 JPWO2022165362A5 (https=) | 2025-02-10 |
Family
ID=82653891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546482A Pending JP2024505570A (ja) | 2021-02-01 | 2022-01-31 | 神経学的疾患及び疼痛を治療するためのエピジェネティック遺伝子調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240366795A1 (https=) |
| EP (1) | EP4284927A4 (https=) |
| JP (1) | JP2024505570A (https=) |
| CN (1) | CN117203334A (https=) |
| AU (1) | AU2022212277A1 (https=) |
| CA (1) | CA3206936A1 (https=) |
| WO (1) | WO2022165362A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024258906A1 (en) * | 2023-04-17 | 2025-11-06 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing nav1.7 expression |
| US20250057981A1 (en) * | 2023-06-26 | 2025-02-20 | Navega Therapeutics, Inc. | Compositions and methods for reducing pain and inflammation through epigenetic modulation |
| WO2025076459A1 (en) * | 2023-10-05 | 2025-04-10 | Navega Therapeutics, Inc. | Compositions and methods for epigenetic modulation of nav1.7 |
| CN119139498B (zh) * | 2024-09-26 | 2025-11-25 | 武汉泓宸创新生物科技有限公司 | 用于治疗与运动神经元损伤相关的疾病的药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9624280B2 (en) * | 2013-10-03 | 2017-04-18 | Janssen Biotech, Inc. | Protoxin-II variants and methods of use |
| WO2018035503A1 (en) * | 2016-08-18 | 2018-02-22 | The Regents Of The University Of California | Crispr-cas genome engineering via a modular aav delivery system |
| CA3106446A1 (en) * | 2017-07-13 | 2019-01-17 | University Of Miami | Method for managing pain |
| US20220202957A1 (en) * | 2019-04-09 | 2022-06-30 | The Regents Of The University Of California | Long-lasting analgesia via targeted in vivo epigenetic repression |
-
2022
- 2022-01-31 JP JP2023546482A patent/JP2024505570A/ja active Pending
- 2022-01-31 AU AU2022212277A patent/AU2022212277A1/en active Pending
- 2022-01-31 WO PCT/US2022/014601 patent/WO2022165362A2/en not_active Ceased
- 2022-01-31 CN CN202280022276.2A patent/CN117203334A/zh active Pending
- 2022-01-31 EP EP22746823.8A patent/EP4284927A4/en active Pending
- 2022-01-31 CA CA3206936A patent/CA3206936A1/en active Pending
- 2022-01-31 US US18/274,978 patent/US20240366795A1/en active Pending